On March 22, 2012, Mymetics Corporation appointed Dr. Christopher S. Henney as a director and Chairman of its Board of Directors and Grant Pickering as a director and President and Chief Executive Officer to pursue new strategic directions, including the potential change of the company's location from Switzerland to the United States, effective November 19, 2012. The company appointed Ronald Kempers, currently its CFO and COO, to be President and Chief Executive Officer, following the departure of Dr. Christopher S. Henney and Grant Pickering in accordance with the terms of their arrangement with the company. The company will maintain its principal place of business in Switzerland as it explores a number of strategic opportunities for its HIV, RSV and other vaccine candidates under development.